Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Linda McAllister, Mostafa Ronaghi

Premium

Linda McAllister has joined Toronto-based molecular diagnostics firm Xagenic as chief medical officer.

McAllister previously has worked on the development and launch of molecular technologies at Roche Diagnostics, Celera Diagnostics, and Affymetrix. She most recently was CMO at the prenatal genetic testing company Cellscape, and she was CMO and VP of R&D at Pharmajet. She also was an adjunct clinical professor in the University of California, San Francisco department of medicine from 1992 to 2005, and a research fellow at Stanford University.


Mostafa Ronaghi has joined BaseHealth's board of directors.

Ronaghi currently serves as Illumina's chief technology officer and senior vice president. Before joining Illumina, he founded several life sciences companies including ParAllele BioScience, which was acquired by Affymetrix, as well as Avantome and NextBio, both of which were acquired by Illumina. He also previously spent nine years as a principal investigator at the Stanford Genome Technology Center.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.